Skip to main content

Table 5 Description and supporting evidence of the KEs included in postulated MoA for BPAF in female adult exposure

From: Assessment of the endocrine disrupting properties of bisphenol AF: a case study applying the European regulatory criteria and guidance

 

Brief description of key event

Supporting evidence

MIE 1

Estrogen receptor activation (two parallel MIEs are suggested, current knowledge in endocrinology does not provide sufficient knowledge to conclude whether they are indeed parallel or whether one of them precedes the other)

In vitro mechanistic:

â– Estrogen receptor binding IDs: 45, 51, 72, 75

●Estrogen receptor agonist activity IDs: 3, 6, 8, 11–15, 17–18, 20–22, 42–44, 46, 48, 52, 62–65, 78, 81, 86–87

●Estrogen dependent cellular proliferation IDs: 7–6, 10, 15, 20, 48, 80

■Estrogen receptor dependent gene/protein expression increased IDs: 9–13, 15, 17–18, 20, 23, 48, 80

In vivo mechanistic:

â– Estrogen receptor dependent gene expression increased (adult exposure) IDs: 59, 83

●Uterus weight increase (adult exposure) IDs: 61–63, 86

â—ŹUterus histopathology alteration (adult exposure) ID: 63

MIE 2

Altered steroidogenesis

In vitro mechanistic:

●Steroidogenesis alteration IDs: 4–5, 87

In vivo mechanistic:

â—ŹSteroidogenesis gene/protein expression alteration (adult exposure) IDs: 55, 58, 83

â—ŹProgesterone level decrease in female (adult exposure) ID: 83

KE1

Ovarian dysfunction

EATS-mediated:

â—ŹOvary histopathology alteration (adult exposure) IDs: 83, 88

â—ŹOvary weight decrease (adult exposure) IDs: 83, 88

KE2

Altered estrous cycling

EATS-mediated:

â—ŹEstrous cycling disruption (adult exposure) IDs: 60, 83, 88

AO

Impaired female fertility

None (no data available, but hypothesized based on current knowledge in endocrinology)